G
Günther G. Steger
Researcher at Medical University of Vienna
Publications - 243
Citations - 11875
Günther G. Steger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 41, co-authored 238 publications receiving 10859 citations. Previous affiliations of Günther G. Steger include University of Vienna.
Papers
More filters
Journal ArticleDOI
Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group
Peter Dubsky,Raimund Jakesz,Brigitte Mlineritsch,Sabine Pöstlberger,Hellmut Samonigg,Werner Kwasny,Christoph Tausch,Herbert Stöger,Karin Haider,Florian Fitzal,Christian F. Singer,Michael Stierer,Paul Sevelda,G. Luschin-Ebengreuth,Susanne Taucher,Margaretha Rudas,Rupert Bartsch,Günther G. Steger,Richard Greil,Lidija Filipcic,Michael Gnant +20 more
TL;DR: Despite a low overall rate of recurrence in a population with breast cancer at limited risk of relapse, the a priori sequence strategy of 2 years of TAM followed by 3 years of ANA led to small outcome and toxicity benefits.
Journal ArticleDOI
Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro
Thomas Brodowicz,Christoph Wiltschke,Alexandra C. Budinsky,Michael Krainer,Günther G. Steger,Christoph C. Zielinski +5 more
TL;DR: The data suggest that tumors rich in HER‐2/neu might thus escape certain steps of immunologic control by neutralizing biologic activities of anti-HER‐2‐neu antibody–mediated inhibition of proliferation due to a binding of soluble HER‐ 2/neU by the antibody.
Journal ArticleDOI
2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study
A. Stopeck,Jean-Jacques Body,Y. Fujiwara,Allan Lipton,Günther G. Steger,M. Viniegra,Michelle Fan,A. Braun,R. Dansey,Susie Jun +9 more
Proceedings ArticleDOI
Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
DJ Slamon,Sandra M. Swain,Marc Buyse,M. Martin,Charles E. Geyer,Y-H Im,Tadeusz Pienkowski,S-B Kim,Nicholas J. Robert,Günther G. Steger,J.P. Crown,S. Verma,Wolfgang Eiermann,Joseph P. Costantino,S-A Im,Eleftherios P. Mamounas,Lee S. Schwartzberg,Ahg Paterson,John R. Mackey,Louise Provencher,Michael F. Press,M. Thirlwell,V. Bee-Munteanu,Volkmar Henschel,A Crepelle-Flechais,Norman Wolmark +25 more
TL;DR: A randomized, phase 3, open-label study evaluating the addition of B to 2 different H-chemo regimens to assess the impact of VEGF-A blockade on residual or micrometastatic disease in the adjuvant setting.
Journal ArticleDOI
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
Walter Schippinger,Hellmut Samonigg,Renate Schaberl-Moser,Richard Greil,R Thödtmann,Joerg Tschmelitsch,M Jagoditsch,Günther G. Steger,Raimund Jakesz,F. Herbst,Friedrich Hofbauer,Hans Rabl,Peter Wohlmuth,Michael Gnant,Josef Thaler +14 more
TL;DR: Results of this trial demonstrate a trend to a lower risk for relapse in patients treated with adjuvant 5-FU/LV for stage II colon cancer, however, in this study with limited power to detect small differences between the study arms, adjUvant chemotherapy failed to significantly improve DFS and OS.